Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $68.85 | Total: $344.25 |
| 1 | 10 | $58.32 | Total: $583.20 |
| 1 | 25 | $49.41 | Total: $1,235.25 |
| 1 | 50 | $42.12 | Total: $2,106.00 |
| 1 | 100 | $36.45 | Total: $3,645.00 |
Overview
Trk-IN-9 (Compound 12) is a potent inhibitor of TRK that inhibits the proliferation of Km-12 cell lines and induces apoptosis in a concentration-dependent manner. It also inhibits TRK phosphorylation and blocks downstream pathways, showing potential for NTRK fusion cancer research.
Chemical Properties
| Molecular Formula | C23H24ClFN6O |
| Molecular Weight | 454.93 |
| CAS Numbers | 2758623-12-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(C=1N=C(NCC2=CC(F)=CC=C2)C(Cl)=CN1)C3=CC(C(N[C@@H]4CCCNC4)=O)=CC=C3 |
Storage and Handling
0C Short Term, -20C Long Term
References
Wu T, et al. Rational drug design to explore the structure-activity relationship [SAR] of TRK inhibitors with 2,4-diaminopyrimidine scaffold. Eur J Med Chem. 2022;230 114096.